Senior Director, HEOR/RWE - Lung

The Opportunity:

The Senior Director, HEOR/RWE is responsible for providing input on the strategy and executing HEOR plans and activities related to all Revolution Medicines assets intended for use in non-small cell lung cancer (NSCLC). They will be accountable for demonstrating the value of Revolution Medicines products to healthcare organizations, allowing them to make informed decisions. They will work closely with the Medical Affairs team as well as other cross-functional teams to optimize the Integrated Evidence Plan (IEP) and to deliver evidence supporting the use of Revolution Medicines products. The candidate must also be able to provide input and strategic guidance on the global value of the product as well as have demonstrated success in evidence generation globally. The Senior Director HEOR/RWE will participate with the matrix team across the function to ensure alignment of all activities with the strategic and tactical plans. This is an exceptional opportunity to contribute to the advancement of healthcare by providing evidence that can shape the future of patient care in oncology.

• Align with Medical Affairs and Development leadership to design research and deliver evidence consistent with the medical strategy and IEP.

• Deliver HEOR/RWE tactics with quality and in alignment with agreed upon timing.

• Provide HEOR/RWE leadership on matrix teams and working groups.

• Work with the HEOR/RWE and Medical Affairs leadership to ensure critical value insights are communicated to key internal teams.

• Provide HEOR evidence which addresses the needs and expectations of key stakeholders such as patients, healthcare providers, payers and Health Technology Assessment (HTA) agencies.

• Effectively present research findings to internal and external stakeholders to improve internal decision making and to promote wider adoption of research findings across external stakeholders.

• Facilitate the communication of the value proposition of Revolution Medicines’ portfolio, allowing key healthcare and formulary professionals to make informed therapeutic decisions.

• Engage and collaborate with external partners including payers, health care providers, thought leaders, patient advocates, and decision-makers to establish/maintain strong partnerships and gather insights into research programs.

• Facilitate and implement real-world research partnership engagements with leading healthcare, academic and payer organizations to co-create value evidence and help drive evidence-based optimal care.

• Stay up to date with and add to the advancements in health economics methodologies and best practices.

• Identify and interface with HEOR & RWE experts and organizations, profile data sources and related organizations as they relate to Revolution Medicines’ portfolio and therapeutic areas.

• Closely monitor new trends in health policy and payer environment, assess competitive data gaps and communicate to the organization, to help Revolution Medicines build industry-leading capabilities and be on the cutting edge of evidence-based medicine and HEOR research.

Required Skills, Experience and Education:

• Deep expertise in health economics, outcomes research, patient-reported outcomes or related fields in the biotechnology or pharmaceutical industry.

• Experience in oncology HEOR and RWE development.

• Minimum 10 years of relevant experience with an advanced degree in a relevant field (MD, PhD, PharmD).

• Track record of high impact publications in HEOR/RWE topics.

• Strong written and interpersonal communication skills, with an ability to present complex technical information clearly.

• Knowledge and experience in managed care, integrated delivery networks, formulary decision-making, and payment/access models.

• Ability to establish relationships with experts in real world evidence (RWE) and therapeutic areas of interest.

Preferred Skills:

• 12+ years of relevant experience in the pharmaceutical/biotech industry.

• Global launch experience.

• Experience related to NSCLC. 

  #LI-Hybrid #LI-VN1